NCT04078178View on ClinicalTrials.gov

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Cognition Disorders in Old AgeMild Cognitive ImpairmentCognitive Decline
Interventions
DIETARY_SUPPLEMENT

Niagen

Nicotinamide Riboside

DIETARY_SUPPLEMENT

Placebo Comparator

Placebo

Trial Locations (1)

02129

Alzheimer's Clinical and Translational Research Unit, Charlestown

All Listed Sponsors
lead

Steven E Arnold, MD

OTHER

NCT04078178 - Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter